Currently out of the existing stock ratings of Thomas Flaten, 91 are a BUY (94.79%), 5 are a HOLD (5.21%).

Thomas Flaten

Work Performance Price Targets & Ratings Chart

Analyst Thomas Flaten, currently employed at LAKE STREET, carries an average stock price target met ratio of 51.32% that have a potential upside of 60.17% achieved within 197 days.

Thomas Flaten’s has documented 183 price targets and ratings displayed on 21 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on EVAX, Evaxion Biotech AS at 20-Oct-2025.

Wall Street Analyst Thomas Flaten

Analyst best performing recommendations are on ENSC (ENSYSCE BIOSCIENCES).
The best stock recommendation documented was for ENSC (ENSYSCE BIOSCIENCES) at 12/1/2021. The price target of $14400 was fulfilled within 8 days with a profit of $9108 (172.11%) receiving and performance score of 215.14.

Average potential price target upside

of $13.79 (82.17%) on CSTL (CASTLE BIOSCIENCES).
of $9.48 (52.51%) on DMTK (DERMTECH).
of $8.06 (54.64%) on BLFS (BIOLIFE SOLUTIONS).

ACHV Achieve Life Sciences BBI Brickell Biotech CTIC CTi Biopharma Corp DMAC DiaMedica Therapeutics DMTK DermTech VCYT Veracyte CSTL Castle Biosciences AQST Aquestive Therapeutics OCX OncoCyte Corp BFRA Biofrontera AG CKPT Checkpoint Therapeutics TCRT Alaunos Therapeutics BLFS BioLife Solutions ENSC Ensysce Biosciences EVAX Evaxion Biotech AS ZIOP ZIOPHARM Oncology ASRT Assertio Therapeutics BTTX Better Therapeutics OPTN OptiNose PSNL Personalis DERM Journey Medical Corp

Show more stocks

Analyst name

Rating

Rating initiation date

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score